Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZTS · against 588 other Healthcare companies listed in US-listed
Ranked #40 of 589 · scores higher than 93% of peers
Bars: peers in each 10-point band of the valuation score27 peers with a valuation score of 80–89, including ZTS · Click a bar to see the companies
Mainly thanks to its earnings yield, free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | ZTS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 7.4% | -4.3% | 94% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 9.7% | -0.8% | 86% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 6.8% | -2.3% | 89% | 20% | |
| Book yieldHigher is better · 587 reported | Not reported | 25.9% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 40 | 126.1B USD | 83 | 62 | |
| 40 | 748M USD | 83 | 62 | |
| 40 | 615M USD | 83 | 48 | |
| 40 | 360M USD | 83 | 67 | |
| 40 | 34.3B USD | 83 | 57 | |
| 46 | 3.5B USD | 82 | 75 | |
| 46 | 100.2B USD | 82 | 57 | |
| 46 | 23.8B USD | 82 | 84 | |
| 49 | 2.5B USD | 81 | 79 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score